Oculis Holding AG Warrants

Oculis Holding AG is a biopharmaceutical company that develops topical treatments for ophthalmic diseases affecting both the back and front of the eye. Its pipeline includes OCS-01 for diabetic macular edema, OCS-02 for dry eye disease, and OCS-05 for acute optic neuritis and other neuro-ophthalmic disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.